ENANTA PHARMACEUTICALS INC (ENTA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$34.9M
Cash & Equivalents
$18.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$398M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07482657 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of... | PHASE2 | Recruiting | 150 |
| NCT07540910 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ... | PHASE1 | Recruiting | 98 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-18 | 8-K | ENANTA PHARMACEUTICALS INC (ENTA) (CIK 0001177648) - EX-99.1 | EDGAR |